China Immunotech Snags ￥45M in Series A Funding Round

According to PEdaily.cn, Beijing-based China Immunotech Biotechnology Co., Ltd. ("China Immunotech") has completed its series A financing of 45 million yuan, led by Jianxin Capital, with participation from Grower Venture Capital and Huacheng Group.

Founded in March 2018, China Immunotech focuses on the development and commercialization of cellular products for immunotherapy of several diseases, including the world's leading chimeric antigen receptor (CAR) -T cell therapy and engineered T-cell receptor (TCR) -T cell therapy. The company has a rich pipeline of TCR-T and CAR-T, targeting blood tumors, solid tumors and virus infection-related diseases.

China Immunotech has two unique technology platforms, STAR-T and TCR-T. The STAR-T platform uses a proprietary structure of antigen receptor complexes, which has significant advantages over traditional CAR-T products in the treatment of blood tumors, such as better efficacy, fewer side effects and easier development and design of multi-target varieties. 

The TCR-T platform focuses on solid tumor treatment. Based on its TCR-T technology, China Immunotech has built the complete antigen epitope prediction platform, multi-HLA tetramer system preparation platform, high-throughput T cell receptor cloning & screening & identification platform. The TCR-T therapy developed by China Immunotech has shown a good therapeutic effect in clinical trials.

Shanghai-based Jianxin Capital is an investment firm focused on the healthcare industry risk investment fund. It has a professional investment team with rich medical and financial investment, management, and entrepreneurial experience. Jianxin Capital focuses on the invested enterprise demand for product development, industrialization, management and financial investment, and a full range of value-added services.

Grower Venture Capital is an industrial fund jointly established by the government of Guangdong province and Tsinghua University. The company mainly invests in high-end equipment manufacturing (industrial robots, intelligent manufacturing equipment, precision processing, and manufacturing), the transformation and upgrading of traditional industries (Internet with traditional manufacturing, high-end industrial design platform), and some strategic emerging industries (new materials, electronic information, biotechnology).